Full Press Release Details
Rule 2.7, 3.10.3, 3.10.4, 3.10.5
application for quotation of additional securities
Information or documents
not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX s property and may be made public.
Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.
| Name of entity | ||||||
| Prima BioMed Ltd ( Company ) | ||||||
| ABN | ||||||
| 90 009 237 889 | ||||||
| We (the entity) give ASX the following information. | ||||||
| Part 1 - All issues | ||||||
| You must complete the relevant sections (attach sheets if there is not enough space). | ||||||
| 1 | + Class of + securities issued or to be issued | 1. Ordinary Shares 2. Ordinary Shares 3. Ordinary Shares | ||||
| 2 | Number of + securities issued or to be issued (if known) or maximum number which may be issued | 1. 857,844 Ordinary Shares 2. 1,814,249 Ordinary Shares 3. 1,634,375 Ordinary Shares |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
| 3 | Principal terms of the + securities (e.g., if options, exercise price and expiry date; if partly paid + securities, the amount outstanding and due dates for payment; if + convertible securities, the conversion price and dates for conversion) | 1. Fully Paid Ordinary Shares 2. Fully Paid Ordinary Shares 3. Fully Paid Ordinary Shares | ||||
| 4 | Do the + securities rank equally in all respects from the date of allotment with an existing + class of quoted + securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | 1. Pari Passu with existing Fully Paid Ordinary Shares 2. Pari Passu with existing Fully Paid Ordinary Shares 3. Pari Passu with existing Fully Paid Ordinary Shares | ||||
| 5 | Issue price or consideration | 1. Nil 2. Nil 3. Nil | ||||
| 6 | Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) | 1. Mr Pete Meyers exercises 4 th tranche of his performance rights which vested to him i.e. 857,844 to convert to ordinary shares, in accordance with shareholder approval received at the AGM on 14 November 2014. 2. Mr Pete Meyers exercises 1 st tranche of his performance rights which vested to him i.e. 1,814,249 to convert to ordinary shares, in accordance with shareholder approval received at the AGM on 25 November 2016. 3. Vesting of Performance Rights under the Executive Incentive Plan into fully paid ordinary shares. |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
| 6a | Is the entity an + eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b 6h in relation to the + securities the subject of this Appendix 3B , and comply with section 6i | Yes | ||||
| 6b | The date the security holder resolution under rule 7.1A was passed | 25 November 2016 | ||||
| 6c | Number of + securities issued without security holder approval under rule 7.1 | N/A | ||||
| 6d | Number of + securities issued with security holder approval under rule 7.1A | N/A | ||||
| 6e | Number of + securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) | 1. 857,844 ordinary shares are issued on exercise of 4 th tranche out of 7,720,588 performance rights approved for Mr Pete Meyers at the AGM on 14 November 2014. 2. 1,814,249 ordinary shares are issued on exercise of 1 st tranche out of 10,023,350 performance rights approved for Mr Pete Meyers at the AGM on 25 November 2016. | ||||
| 6f | Number of + securities issued under an exception in rule 7.2 | 3. 1,634,375 issued under exception 9 in rule 7.2 | ||||
| 6g | If + securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the + issue date and both values. Include the source of the VWAP calculation. | N/A |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
| 6h | If + securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements | N/A | ||||||||
| 6i | Calculate the entity s remaining issue capacity under rule 7.1 and rule 7.1A complete Annexure 1 and release to ASX Market Announcements | Refer Annexure 1 | ||||||||
| 7 | + Issue dates Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. Cross reference: item 33 of Appendix 3B. | 3 October 2017 | ||||||||
| Number | + Class | |||||||||
| 8 | Number and + class of all + securities quoted on ASX ( including the securities in clause 2 if applicable) | 2,362,662,532 | Ordinary fully paid shares (ASX: PRR) | |||||||
| Number | +Class Options | |||||||||
| Amount | Exercise Price | Expiration Date | ||||||||
| 9 | Number and + class of all + securities not quoted on the ASX (including the securities in clause 2 if applicable) | 1,515,752 | $0.0774 | 30 June 2018 | ||||||
| 165,116 | $0.0774 | 30 June 2018 | ||||||||
| 147,628,500 | $0.05019 | 12 December 2018 | ||||||||
| 371,445,231 | $0.0237 | 4 August 2020 | ||||||||
| 793103 | $0.057 | 30 October 2020 | ||||||||
| 1,026,272 | $0.040 | 7 March 2021 | ||||||||
| 8,475,995 | $0.025 | 4 August 2025 | ||||||||
| Number | +Class Warrants over NASDAQ listed American Depository Shares | |||||||||
| Amount | Exercise Price | Terms | ||||||||
| 1,973,451 | US$2.50 | Each Warrant entitles the holder to purchase 1 ADS (where one ADS = 100 Ordinary Shares) at the exercise price and is exercisable immediately. Each Warrant will expire 5.5 years from the date of issuance. | ||||||||
| Number | +Class Performance Rights | |||||||||
| Amount | Type | Expiration Date | ||||||||
| 3,900,000 | STI | 30 November 2018 | ||||||||
| 16,731,373 | LTI | 30 October 2018 |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
| 8,209,101 | NED PRs | Each tranche of NED PRs will expire one year after Vesting Date if not exercised as indicated in the appendix 3B released on 6 December 2016. | ||||||||
| Number | + Class Convertible Notes | |||||||||
| Amount | Type | Expiration Date | ||||||||
| 13,750,828 | Convertible Notes each with a face value of AU$1, expiring on 4 August 2025 | |||||||||
| 10 | Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests) | Unchanged | ||||||||
| Part 2 - Bonus issue or pro rata issue | ||||||||||
| 11 | Is security holder approval required? | Not applicable | ||||||||
| 12 | Is the issue renounceable or non-renounceable? | Not applicable | ||||||||
| 13 | Ratio in which the + securities will be offered | Not applicable | ||||||||
| 14 | + Class of + securities to which the offer relates | Not applicable | ||||||||
| 15 | + Record date to determine entitlements | Not applicable | ||||||||
| 16 | Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? | Not applicable | ||||||||
| 17 | Policy for deciding entitlements in relation to fractions | Not applicable | ||||||||
| 18 | Names of countries in which the entity has + security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. | Not applicable | ||||||||
| 19 | Closing date for receipt of acceptances or renunciations | Not applicable |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
| 20 | Names of any underwriters | Not applicable | ||||
| 21 | Amount of any underwriting fee or commission | Not applicable | ||||
| 22 | Names of any brokers to the issue | Not applicable | ||||
| 23 | Fee or commission payable to the broker to the issue | Not applicable | ||||
| 24 | Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of + security holders | Not applicable | ||||
| 25 | If the issue is contingent on + security holders approval, the date of the meeting | Not applicable | ||||
| 26 | Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled | Not applicable | ||||
| 27 | If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders | Not applicable | ||||
| 28 | Date rights trading will begin (if applicable) | Not applicable | ||||
| 29 | Date rights trading will end (if applicable) | Not applicable | ||||
| 30 | How do + security holders sell their entitlements in full through a broker? | Not applicable | ||||
| 31 | How do + security holders sell part of their entitlements through a broker and accept for the balance? | Not applicable |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
| 32 | How do + security holders dispose of their entitlements (except by sale through a broker)? | Not applicable | ||||||
| 33 | + Despatch date | Not applicable | ||||||
| Part 3 - Quotation of securities | ||||||||
| You need only complete this section if you are applying for quotation of securities |
| 34 | Type of securities ( tick one ) | |||||||
| (a) | Securities described in Part 1 | |||||||
| (b) | All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities | |||||||
| Entities that have ticked box 34(a) | ||||||||
| Additional securities forming a new class of securities | ||||||||
| Tick to indicate you are providing the information or documents | ||||||||
| 35 | If the + securities are + equity securities, the names of the 20 largest holders of the additional + securities, and the number and percentage of additional + securities held by those holders | |||||||
| 36 | If the + securities are + equity securities, a distribution schedule of the additional + securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over | |||||||
| 37 | A copy of any trust deed for the additional + securities |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
| Entities that have ticked box 34(b) | ||||||
| 38 | Number of securities for which + quotation is sought | Not applicable | ||||
| 39 | Class of + securities for which quotation is sought | Not applicable | ||||
| 40 | Do the + securities rank equally in all respects from the date of allotment with an existing + class of quoted + securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | Not applicable |
| 41 | Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) | Not applicable | ||||||
| Number | + Class | |||||||
| 42 | Number and + class of all + securities quoted on ASX ( including the securities in clause 38) | Not applicable |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give
| Sign here: | Date: 3 October 2017 | |||||||
| Company secretary | ||||||||
| Print name: | Tom Bloomfield |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
Appendix 3B Annexure 1
Calculation of placement capacity under
rule 7.1 and rule 7.1A for eligible entities
Introduced 01/08/12 Amended 04/03/13
| Rule 7.1 Issues exceeding 15% of capital | ||||
| Step 1: Calculate A , the base figure from which the placement capacity is calculated | ||||
| Insert number of fully paid + ordinary securities on issue 12 months before the + issue date or date of agreement to issue | 2,068,964,280 | |||
| Add the following: | ||||
| Number of fully paid + ordinary securities issued in that 12 month period under an exception in rule 7.2 | ||||
| Number of fully paid + ordinary securities issued in that 12 month period with shareholder approval | 30,571,452 | |||
| Number of partly paid + ordinary securities that became fully paid in that 12 month period Note: Include only ordinary securities here other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | ||||
| Subtract the number of fully paid + ordinary securities cancelled during that 12 month period | Nil | |||
| A | 2,099,535,732 |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
| Step 2: Calculate 15% of A | ||||
| B | 0.15 [Note: this value cannot be changed] | |||
| Multiply A by 0.15 | 314,930,360 | |||
| Step 3: Calculate C , the amount of placement capacity under rule 7.1 that has already been used | ||||
| Insert number of + equity securities issued or agreed to be issued in that 12 month period not counting those issued: Under an exception in rule 7.2 Under rule 7.1A With security holder approval under rule 7.1 or rule 7.4 Note: This applies to equity securities, unless specifically excluded not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items | 311,961,441 | |||
| C | 311,961,441 | |||
| Step 4: Subtract C from [ A B ] to calculate remaining placement capacity under rule 7.1 | ||||
| A 0.15 Note: number must be same as shown in Step 2 | 314,930,360 | |||
| Subtract C Note: number must be same as shown in Step 3 | 311,961,441 | |||
| Total [ A 0.15] C | 2,968,919 Note: this is the remaining placement capacity under rule 7.1 |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
| Rule 7.1A Additional placement capacity for eligible entities | ||
| Step 1: Calculate A , the base figure from which the placement capacity is calculated | ||
| A Note: number must be same as shown in Step 1 of Part 1 | 2,099,535,732 | |
| Step 2: Calculate 10% of A | ||
| D | 0.10 Note: this value cannot be changed | |
| Multiply A by 0.10 | 209,953,573 | |
| Step 3: Calculate E , the amount of placement capacity under rule 7.1A that has already been used | ||
| Insert number of + equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: This applies to equity securities not just ordinary securities Include here if applicable the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items | 148,510,459 | |
| E | 148,510,459 |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
| Step 4: Subtract E from [ A x D ] to calculate remaining placement capacity under rule 7.1A | ||
| A x 0.10 Note: number must be same as shown in Step 2 | 209,953,573 | |
| Subtract E Note: number must be same as shown in Step 3 | 148,510,459 | |
| Total [ A x 0.10] E | 61,443,114 Note: this is the remaining placement capacity under rule 7.1A |
Level 12, 95 Pitt St, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) ( Prima or the Company ) Prima advises that in
relation to the issuance of ordinary shares as further detailed in the preceding Appendix 3B, the Company gives notice under section 708A(5)(e) of the Corporations Act 2001(Cth) (the Corporations Act ) that:
Level 12, 95 Pitt Street, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889